Learn More
Learn More
High content readouts of electrophysiological and transcriptomic changes in human cerebral organoids enable preclinical functional testing of neurotheurapeutics in human brain tissue.
Discover how high content readouts of electrophysiological and transcriptomic changes
in human cerebral organoids enable preclinical functional testing of neurotheurapeutics in human brain tissue.
High content readouts of electrophysiological and transcriptomic changes in human cerebral organoids enable preclinical functional testing of neurotheurapeutics in human brain tissue.
Home
About
Contact
Team
Our solutions are at the intersection of tissue engineering, neural signal processing, and bioinformatics
Our solutions are at the intersection of tissue engineering, neural signal processing, and bioinformatics
Automated Electrographic Analysis
Automated Electrographic Analysis
Automated Electrographic Analysis
Read About It
Read About It
Our competitive advantage rests in our trade secret electrophysiological algorithms, in order to identify the markers of neurological disease. We have published and released into the public domain a methodology on generating hyperexcitable brain organoids, and are working towards optimizing the methodology in order to file a provisional patent on our model of epilepsy in organoids.
Our competitive advantage rests in our trade secret electrophysiological algorithms, in order to identify the markers of neurological disease. We have published and released into the public domain a methodology on generating hyperexcitable brain organoids, and are working towards optimizing the methodology in order to file a provisional patent on our model of epilepsy in organoids.
With Epiloid, our solution is to develop preclinical brain organoid models of neurological disease for direct testing with new therapeutics. These brain organoids are essentially miniature 3D human brain tissues that can be grown in a dish from human stem cells, or even as little as a drop of patient blood. Brain organoids retain many of the essential features of the adult brain needed to evaluate preclinical drug effects. This means we can treat a diseased human organoid with a new drug, evaluate how the organoid's electrical and protein expression respond to the drug in order to combat the disease, and provide that functional insight on human drug efficacy back to pharmaceutical developers before they invest in costly clinical trials.
With Epiloid, our solution is to develop preclinical brain organoid models of neurological disease for direct testing with new therapeutics. These brain organoids are essentially miniature 3D human brain tissues that can be grown in a dish from human stem cells, or even as little as a drop of patient blood. Brain organoids retain many of the essential features of the adult brain needed to evaluate preclinical drug effects. This means we can treat a diseased human organoid with a new drug, evaluate how the organoid's electrical and protein expression respond to the drug in order to combat the disease, and provide that functional insight on human drug efficacy back to pharmaceutical developers before they invest in costly clinical trials.
Pharmaceutical companies spend between ~$0.8-1.6B per new neurology drugs, of which >90% fail, the drug never reaching market. The most cited factors in this failure is poor translation from preclinical models to human patients, specifically in predicting human toxicity and human efficacy.
Pharmaceutical companies spend between ~$0.8-1.6B per new neurology drugs, of which >90% fail, the drug never reaching market. The most cited factors in this failure is poor translation from preclinical models to human patients, specifically in predicting human toxicity and human efficacy.
Why We're Better
Our competitive advantage rests in our trade secret electrophysiological algorithms, in order to identify the markers of neurological disease. We have published and released into the public domain a methodology on generating hyperexcitable brain organoids, and are working towards optimizing the methodology in order to file a provisional patent on our model of epilepsy in organoids.
With Epiloid, our solution is to develop preclinical brain organoid models of neurological disease for direct testing with new therapeutics. These brain organoids are essentially miniature 3D human brain tissues that can be grown in a dish from human stem cells, or even as little as a drop of patient blood. Brain organoids retain many of the essential features of the adult brain needed to evaluate preclinical drug effects. This means we can treat a diseased human organoid with a new drug, evaluate how the organoid's electrical and protein expression respond to the drug in order to combat the disease, and provide that functional insight on human drug efficacy back to pharmaceutical developers before they invest in costly clinical trials.
Pharmaceutical companies spend between ~$0.8-1.6B per new neurology drugs, of which >90% fail, the drug never reaching market. The most cited factors in this failure is poor translation from preclinical models to human patients, specifically in predicting human toxicity and human efficacy.
Why We're Better